Resveratrol Butyrate Esters Reduce Hypertension in a Juvenile Rat Model of Chronic Kidney Disease Exacerbated by Microplastics
Nutrients · 2024
DOI: 10.3390/nu16234076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Yi-Ning Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan. Hauptthemen laut MEDLINE: Rats, Sprague-Dawley, Renal Insufficiency, Chronic, Hypertension, Resveratrol. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaohsiung Chang Gung Memorial Hospital, Taiwan.
Abstract (Originalsprache)
Background
Resveratrol is recognized as a promising nutraceutical with antihypertensive and prebiotic properties; however, its bioavailability in vivo is limited. To enhance its bioactivity, we developed resveratrol butyrate esters (RBEs). This study investigates whether RBEs can mitigate hypertension induced by chronic kidney disease (CKD) and exacerbated by microplastics (MPs) exposure in juvenile rats.
Methods
Three-week-old male Sprague Dawley rats were fed either regular chow or 0.5% adenine chow for three weeks. The adenine-fed CKD rats (N = 8 per group) received either 5 μM MPs (10 mg/L) or MPs combined with RBE (25 mg/L) in their drinking water from weeks 3 to 9.
Results
Our results indicate that MP exposure worsened CKD-induced hypertension, while RBE treatment resulted in a reduction in systolic BP by 15 mmHg (155 ± 2 mmHg vs. 140 ± 1 mmHg, p < 0.05). The combined exposure to adenine and MPs was associated with nitric oxide (NO) deficiency, which RBE treatment alleviated. Additionally, our findings revealed that RBE modulated both the classical and nonclassical renin–angiotensin system (RAS), contributing to its protective effects. We also observed changes in gut microbiota composition, increased butyric acid levels, and elevated renal GPR41 expression associated with RBE treatment.
Conclusions
In conclusion, in this juvenile rat model of combined CKD and MP exposure, RBE demonstrates antihypertensive effects by modulating NO levels, the RAS, gut microbiota, and their metabolites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan.
- Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan.
- School of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
- Department of Seafood Science, National Kaohsiung University of Science and Technology, Kaohsiung 811, Taiwan.
- Department of Food Science, National Pingtung University of Science and Technology, Pingtung 912, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan 330, Taiwan.
ORCID-Profile: Chien-Ning Hsu, Chih-Yao Hou, Shin-Yu Chen, You-Lin Tain
Förderung
- Kaohsiung Chang Gung Memorial Hospital, Taiwan
Zitieren
APA
Huang, Y. N., Hsu, C. N., Hou, C. Y., Chen, S. Y., & Tain, Y. L. (2024). Resveratrol Butyrate Esters Reduce Hypertension in a Juvenile Rat Model of Chronic Kidney Disease Exacerbated by Microplastics. Nutrients. https://doi.org/10.3390/nu16234076
Vancouver
Huang YN, Hsu CN, Hou CY, Chen SY, Tain YL. Resveratrol Butyrate Esters Reduce Hypertension in a Juvenile Rat Model of Chronic Kidney Disease Exacerbated by Microplastics. Nutrients. 2024. doi:10.3390/nu16234076
BibTeX
@article{Huang2024,
author = {Huang, Yi-Ning and Hsu, Chien-Ning and Hou, Chih-Yao and Chen, Shin-Yu and Tain, You-Lin},
title = {Resveratrol Butyrate Esters Reduce Hypertension in a Juvenile Rat Model of Chronic Kidney Disease Exacerbated by Microplastics},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16234076}
}
EUVIMED